Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cancergencyto.2009.08.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of Philadelphia Chromosome-Positive B-Lymphoblastic Leukemia Diagnosed in an Infant.
Pediatr Blood Cancer
January 2025
Division of Pediatric Hematology/Oncology, Stead Family Department of Pediatrics, University of Iowa, Iowa City, Iowa, USA.
[Acquisition of Primary Ph Bone Marrow Cells and Establishment of Ph B-ALL Mouse Model].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Blood Disease Institute, Xuzhou Medical University,Xuzhou 221000, Jiangsu Province, China.
Article Synopsis
- The objective of the study was to harvest primary Philadelphia chromosome-positive (Ph) cells from B-acute lymphoblastic leukemia (B-ALL) and create a B-ALL mouse model.
- Methods included infecting bone marrow cells from C57BL/6J mice with a retrovirus, followed by the transplantation of transfected cells into irradiated mice, resulting in the establishment of multiple generations of Ph cells.
- The results showed significant health deterioration in the mice post-transplant, with pathological features such as weight loss and leukemic cell infiltration in the liver, confirming the successful creation of a B-ALL mouse model through progressive passages of Ph cells.
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model.
Br J Clin Pharmacol
December 2024
Novartis Pharma AG, Basel, Switzerland.
Aims: This study aims to evaluate the exposure-efficacy relationship of nilotinib and longitudinal BCR::ABL1 levels in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (CML-CP) and those who are imatinib-resistant or intolerant using a semimechanistic disease model.
Methods: The analysis included 489 CML-CP patients from 3 nilotinib trials (NCT00109707; NCT00471497; NCT01043874) with duration of follow-up ranging from 2 to 9 years. The semimechanistic disease model of CML-CP consisted of quiescent leukaemic stem cells, proliferating drug-susceptible and -resistant bone marrow cells.
Epstein-Barr virus-associated lymphoproliferative disease during remission after induction therapy with dasatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report.
Ann Hematol
December 2024
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Dasatinib, a second-generation tyrosine kinase inhibitor, has been reported to have immunomodulatory effects. Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (EBV-LPD) occur in immunocompromised patients, such as those receiving methotrexate or other immunosuppressive drugs or after allogenic transplantation. EBV-LPD is also reported to be a rare side effect in patients receiving long-term dasatinib or imatinib.
View Article and Find Full Text PDFPhiladelphia Chromosome as a Clinically Favorable Prognostic Factor of B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Transplant-Ineligible Elderly Patients in the Era of Molecular-Targeted Therapy.
Cureus
November 2024
Department of Hematology, Oita Prefectural Hospital, Oita, JPN.
Background and objective There is scarce data on the treatment outcomes of B-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (B-ALL/LBL) in elderly patients in the era of tyrosine kinase inhibitors (TKIs), blinatumomab, and inotuzumab ozogamicin. In light of this, we aimed to address this gap in data by conducting this retrospective study. Methods Treatment outcomes were retrospectively evaluated by using data from transplant-ineligible patients aged 65 years or older with newly diagnosed B-ALL/LBL (n=29) at two hospitals in Oita, Japan between 2013 and 2023.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!